Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neu Base Therapeutics Inc (NBSE)

Neu Base Therapeutics Inc (NBSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,418
  • Shares Outstanding, K 3,752
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,370 K
  • 60-Month Beta 0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.15
Trade NBSE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.21
  • Most Recent Earnings $-0.95 on 11/09/23
  • Next Earnings Date 09/23/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3600 +5.00%
on 05/06/24
0.4653 -18.76%
on 04/15/24
-0.0232 (-5.78%)
since 04/10/24
3-Month
0.3600 +5.00%
on 05/06/24
1.1500 -67.13%
on 03/20/24
-0.3020 (-44.41%)
since 02/09/24
52-Week
0.3600 +5.00%
on 05/06/24
4.8000 -92.13%
on 05/22/23
-3.4200 (-90.05%)
since 05/10/23

Most Recent Stories

More News
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE

/PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics...

NBSE : 0.3780 (-3.20%)
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE

/CNW/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc....

NBSE : 0.3780 (-3.20%)
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data...

NBSE : 0.3780 (-3.20%)
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO

PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a...

NBSE : 0.3780 (-3.20%)
NeuBase to Participate at the Jefferies Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a...

NBSE : 0.3780 (-3.20%)
NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic...

NBSE : 0.3780 (-3.20%)
NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology...

NBSE : 0.3780 (-3.20%)
NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal

A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride...

NBSE : 0.3780 (-3.20%)
NeuBase to Present at Oppenheimer’s 32nd Annual Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a...

NBSE : 0.3780 (-3.20%)
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to...

NBSE : 0.3780 (-3.20%)

Business Summary

NeuBase Therapeutics Inc. is a biotechnology company. It is engaged in developing antisense therapies to address genetic diseases. The company's proprietary platform includes PATrOL(TM). NeuBase Therapeutics Inc., formerly known as Ohr Pharmaceutical Inc., is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 0.4177
2nd Resistance Point 0.4045
1st Resistance Point 0.3913
Last Price 0.3780
1st Support Level 0.3649
2nd Support Level 0.3517
3rd Support Level 0.3385

See More

52-Week High 4.8000
Fibonacci 61.8% 3.1039
Fibonacci 50% 2.5800
Fibonacci 38.2% 2.0561
Last Price 0.3780
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar